All In Biotech

Drug Trial Radar · NCT05629559

4D-310 in Adults With Fabry Disease and Cardiac Involvement

An Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement

Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Oct 16, 2022

Primary completion

Jun 2026

Study completion Jun 2030

Sponsor

Lead sponsor
4D Molecular TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement

Conditions

  • Fabry Disease

Interventions

  • 4D-310Biological

    Single IV administration of 4D-310

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse eventsTime frame: 1 year

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Royal Melbourne Hospital

    Melbourne, Australia · Active not recruiting

  • Royal Perth Hospital

    Perth, Australia · Active not recruiting

  • Westmead Hospital

    Westmead, Australia · Not yet recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.